Clinical Trial Info

An Immunogenicity and Safety Study of Sabin Inactivated Poliovirus Vaccine (Vero Cell) in 2-month-old Infants

Authored by
Staff

The study is a randomized, double-blind, controlled randomized, double-blind, controlled clinical trial. The purpose of this study is to evaluate the immunogenicity and safety of Sabin Inactivated Poliovirus Vaccine (Vero cell) manufactured by Sinovac Vaccine Technology Co., Ltd in 2-month-old infants.

The control vaccine is a commercialized Inactivated Poliovirus Vaccine manufactured by Sanofi Pasteur company.

1200 healthy infants between 60-90 days will be randomly assigned into the experimental group or control group in the ratio 1:1.